To validate if the enhanced effect of combination therapy on cell viability was due to cell death, apoptosis and necrosis induction was measured at 5 days post-PRRT in GOT1 and BON1-SSTR2 cells, two cell lines from our panel that are derived from neuroendocrine tumors (Figure 1B; Figure S3). The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.